Medtronic, BCBS Minnesota ink value-based diabetes deal

Medtronic (NYSE:MDT) said today that it inked a deal with Blue Cross & Blue Shield of Minnesota on an outcomes-based program for diabetes patients.

The plan gives BCBS Minnesota members access to Medtronic’s Guardian Connect continuous glucose monitor via a pharmacy benefit, with payments pegged to how long patients spend in a targeted blood glucose range. The deal also includes access to the company’s Inner Circle patient engagement program, which aims to use gamification to improve outcomes, for people using Guardian Connect and Medtronic’s MiniMed 670G pump.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic, BCBS Minnesota ink value-based diabetes deal appeared first on MassDevice.

from MassDevice http://bit.ly/2I5E0lL